19. Chen H., Strickland A.L., Castrillon D.H. Histopathologic diagnosis of endometrial precancers: updates and future directions. Semin Diagn Pathol. 2022; 39 (3): 137–47. DOI: https://doi.org/10.1053/j.semdp.2021.12.001
20. Aguilar M., Zhang H., Zhang M., et al. Serial genomic analysis of endometrium supports the existence of histologically indistinct endometrial cancer precursors. J Pathol. 2021; 254: 20–30. DOI: https://doi.org/10.1002/path.5628
21. Strickland A.L., Rivera G., Lucas E., et al. PI3K Pathway effectors pAKT and FOXO1 as novel markers of endometrioid intraepithelial neoplasia. Int J Gynecol Pathol. 2019; 38: 503–13. DOI: https://doi.org/10.1097/PGP.0000000000000549
22. Raffone A., Travaglino A., Saccone G., et al. PAX2 in endometrial carcinogenesis and in differential diagnosis of endometrial hyperplasia: a systematic review and meta-analysis of diagnostic accuracy. Acta Obstet Gynecol Scand. 2019; 98: 287–99. DOI: https://doi.org/10.1111/aogs.13512
23. Costigan D.C., Dong F., Nucci M.R., Howitt B.E. Clinicopathologic and immunohistochemical correlates of CTNNB1 mutated endometrial endometrioid carcinoma. Int J Gynecol Pathol. 2020; 39: 119–27. DOI: https://doi.org/10.1097/PGP.0000000000000583
24. Kim G., Kurnit K.C., Djordjevic B., et al. Nuclear beta-catenin localization and mutation of the CTNNB1 gene: a context-dependent association. Mod Pathol. 2018; 31: 1553–9. DOI: https://doi.org/10.1038/s41379-018-0080-0
25. Wright M.F., Fitzlaff S., Wyeth A., et al. Nuclear beta-catenin expression in endometrioid intraepithelial neoplasia (atypical hyperplasia) does not predict carcinoma on subsequent hysterectomy. Int J Gynecol Pathol. 2021; 40: 240–7. DOI: https://doi.org/10.1097/PGP.0000000000000695
26. Aguilar M., Chen H., Rivera-Colon G., et al. Reliable identification of endometrial precancers through combined Pax2, beta-catenin, and Pten immunohistochemistry. Am J Surg Pathol. 2022; 46 (3): 404–14. DOI: https://doi.org/10.1097/PAS.0000000000001810
27. Raffone A., Travaglino A., Saccone G., et al. Diagnostic and prognostic value of ARID1A in endometrial hyperplasia: a novel marker of occult cancer. APMIS. 2019; 127: 597–606. DOI: https://doi.org/10.1111/apm.12977
28. Ayhan A., Mao T.L., Suryo Rahmanto Y., et al. Increased proliferation in atypical hyperplasia/endometrioid intraepithelial neoplasia of the endometrium with concurrent inactivation of ARID1A and PTEN tumour suppressors. J Pathol Clin Res. 2015; 1 (3): 186–93. DOI: https://doi.org/10.1002/cjp2.22
29. Ponomarenko I.V., Polonikov A.V., Churnosov M.I. Association of ESR2 gene RS4986938 polymorphism with the development of endometrial hyperplasia. Akusherstvo i ginekologiya [Obstetrics and Gynecology]. 2019; (4): 66–72. DOI: https://doi.org/10.18565/aig.2019.4.66-72 (in Russian)
30. Zaino R.J., Brady W.E., Todd W., et al. Histologic effects of medroxyprogesterone acetate on endometrioid endometrial adenocarcinoma: a Gynecologic Oncology Group study. Int J Gynecol Pathol. 2014; 33: 543–53. DOI: https://doi.org/10.1097/PGP.0000000000000177
31. Chen H., Lucas E., Strickland A.L., et al. Specific biomarker expression patterns in the diagnosis of residual and recurrent endometrial precancers after progestin treatment: a longitudinal study. Am J Surg Pathol. 2020; 44: 1429–39. DOI: https://doi.org/10.1097/PAS.0000000000001537
32. Chatzipantelis P., Koukourakis M., Balaska K., Giatromanolaki A. Endometrial stromal expression of ER, PR, and B-catenin toward differentiating hyperplasia diagnoses. Int J Surg Pathol. 2022; 30 (5): 492–8. DOI: https://doi.org/10.1177/10668969211065110
33. Hiruma S., Kamasaki T., Otomo K., et al. Dynamics and function of ERM proteins during cytokinesis in human cells. FEBS Lett. 2017; 591 (20): 3296–309. DOI: https://doi.org/10.1002/1873-3468.12844
34. Agacayak E., Keles A., Deger U., et al. Could moesin be a new marker for indicating progression in endometrial cancer? Cancer Manag Res. 2022; 24 (14): 1247–57. DOI: https://doi.org/10.2147/CMAR.S353225
35. Cuylen S., Blaukopf C., Politi A.Z., et al. Ki-67 acts as a biological surfactant to disperse mitotic chromosomes. Nature. 2016; 535 (7611): 308–12. DOI: https://doi.org/10.1038/nature18610
36. Li L.T., Jiang G., Chen Q., Zheng J.N. Ki67 is a promising molecular target in the diagnosis of cancer. Mol Med Rep. 2015; 11 (3): 1566–72. DOI: https://doi.org/10.3892/mmr.2014.2914
37. Ghalib Farhood R., Abd Ali Al-Humairi I. Immunohistochemical study of Ki-67 in hyperplastic and endometrium carcinoma: a comparative study. Arch Razi Inst. 2022; 77 (1): 229–34. DOI: https://doi.org/10.22092/ARI.2021.356540.1865
38. Hassan W.A., Ibrahim R. Expression of CD117, CD34, and VEGF proteins in progression from endometrial hyperplasia to endometrioid carcinoma. Int J Clin Exp Pathol. 2020; 13 (8): 2115–22.
39. Hayes J., Peruzzi P.P., Lawler S. MicroRNAs in cancer: biomarkers, functions and therapy. Trends Mol Med. 2014; 20: 460–9. DOI: https://doi.org/10.1016/j.molmed.2014.06.005
40. Jayaraman M., Radhakrishnan R., Mathews C.A., et al. Identification of novel diagnostic and prognostic miRNA signatures in endometrial cancer. Genes Cancer. 2017; 8: 566–76. DOI: https://doi.org/10.18632/genesandcancer.144
41. Giglio S., Annibali V., Cirombella R., et al. miRNAs as candidate biomarker for the accurate detection of atypical endometrial hyperplasia/endometrial intraepithelial neoplasia. Front Oncol. 2019; 21 (9): 526. DOI: https://doi.org/10.3389/fonc.2019.00526
42. Principe D.R., Doll J.A., Bauer J., et al. TGF-β: duality of function between tumor prevention and carcinogenesis. J Natl Cancer Inst. 2014; 106 (2): 369. DOI: https://doi.org/10.1093/jnci/djt369
43. Shruthi B.S., Vinodhkumar P. Proteomics: a new perspective for cancer. Adv Biomed Res. 2016; 19 (5): 67. DOI: https://doi.org/10.4103/2277-9175.180636
44. Muinelo-Romay L., Casas-Arozamena C., Abal M. Liquid biopsy in endometrial cancer: new opportunities for personalized oncology. Int J Mol Sci. 2018; 19 (8): 2311. DOI: https://doi.org/10.3390/ijms19082311
45. Akkour K., Alanazi I.O., Alfadda A.A. Tissue-based proteomic profiling in patients with hyperplasia and endometrial cancer. Cells. 2022; 11 (13): 2119. DOI: https://doi.org/10.3390/cells11132119
46. Yamane T., Asanoma K., Kobayashi H., et al. Identification of the critical site of calponin 1 for suppression of ovarian cancer properties. Anticancer Res. 2015; 35: 5993–9.
47. Liu H., Li D., Zhou L., et al. LMNA functions as an oncogene in hepatocellular carcinoma by regulating the proliferation and migration ability. J Cell Mol Med. 2020; 24: 12 008–19. DOI: https://doi.org/10.1111/jcmm.15829
48. Cicchillitti L., Corrado G., Carosi M., et al. Prognostic role of NF-YA splicing isoforms and lamin A status in low grade endometrial cancer. Oncotarget. 2016; 8 (5): 7935–45. DOI: https://doi.org/10.18632/oncotarget.13854
49. Matsumoto A., Hieda M., Yokoyama Y., et al. Global loss of a nuclear lamina component, lamin A/C, and LINC complex components SUN1, SUN2, and nesprin-2 in breast cancer. Cancer Med. 2015; 4: 1547–57. DOI: https://doi.org/10.1002/cam4.495
50. Liu J., Zhang Y., Li Q., Wang Y. Transgelins: cytoskeletal associated proteins implicated in the metastasis of colorectal cancer. Front Cell Dev Biol. 2020; 8: 573859. DOI: https://doi.org/10.3389/fcell.2020.573859